At HaemaLogiX, we are committed to maintaining the highest standards of corporate governance to ensure transparency, accountability, and integrity across all aspects of our business. Our governance framework supports effective decision-making and is designed to protect the interests of our shareholders, partners, and patients.
This section outlines the company's governance policies, board structure, charters, and key documents that guide our leadership and operations. We believe strong governance is essential for long-term success and the responsible development of our innovative therapies.
HaemaLogiX's governance framework follows the ASX Corporate Governance Council's Principles and Recommendations (4th edition), with any departures disclosed in the Company's Prospectus. The Board operates three standing committees — Audit and Risk, Nomination and Remuneration, and Scientific and Technology — each under its own charter. The Audit and Risk Committee is chaired by Bryce Carmine.
HaemaLogiX's trials operate under Australian TGA regulation and follow ICH Good Clinical Practice guidelines. Each trial requires Human Research Ethics Committee approval before enrolment, and patients provide informed consent under the Declaration of Helsinki. The KOALA Phase 1 trial is sponsored and conducted by Peter MacCallum Cancer Centre. Adverse-event reporting follows Australian and international standards.
HaemaLogiX's Board comprises seven Directors, two of whom — Dr Geoff Nichol and Dr Laurence Turka — are considered independent under the ASX Principles. The Board Charter provides that, where practical, a majority will be independent; the Company has disclosed in its Prospectus that the current composition departs from this, reflecting the value of its co-founder Directors' institutional knowledge at this stage.
All HaemaLogiX research and clinical activities operate under national and international ethics frameworks, including HREC-approved protocols and TGA-regulated standards. The Company has adopted Whistleblower and Privacy Policies, and the Audit and Risk Committee oversees compliance and risk management. Scientific oversight is provided by the Scientific Advisory Board.